Navigation Links
Macroglobulinemia in Medical News

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...d with chlorambucil in patients with previously untreated CLL. In NHL, an ongoing Phase II study will assess ofatumumab in patients with Waldenstrom's macroglobulinemia - a rare type of slow-growing NHL.(8) Finally, a Phase II study is evaluating ofatumumab plus ICE or DHAP chemotherapy regimen in relapsed/refractory ...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...ER 6th Abstract 1010 TITLE: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom macroglobulinemia (WM) Session Name: Biologic Therapies for NHL (Excluding Pre-clinical Models) Presentation Time: 5:30 PM - 7:30 PM Location: Moscone Center, Hall...

Risk of Lymphoma Increases With Hepatitis C Virus Infection

...nd that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenstrm's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Medical Technology

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in patients with relapsed / refractory Waldenstroms Macroglobulinemia NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nas...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held in Kos, Greece demonstrates clinical activity of perifosine in combination with bortezomib, dexamethasone and lenalidomide plus dexamethasone, in patients with relapsed/refractory multiple myeloma, and as a single agent in patients with...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...l Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a me...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...Centers-Midtown: Phase II study of oral Panobinostat in adult patients with advanced refractory multiple myeloma Waldenstrom macroglobulinemia Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II trial of combination of Bortezomib and Rituximab in relapsed...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...ferent underlying anemias will also be presented RAD001 data demonstrating benefit in patients with relapsed and/or refractory Waldenstrom macroglobulinemia (ASH Abstract #1011 ; Saturday, December 6, 2008; 5:30 - 7:30 PM PST) More than 10 abstracts on p anobinostat ( LBH589 ), showing e...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

....D., Rocky Mountain Cancer Centers-Rose, and John Mattern, D.O., Virginia Oncology Associates-Newport News: Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180 About US Oncology Research The US Oncology Research netw...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

...established agents in patients with relapsed MCL, indolent NHL and Waldenstrom's Macroglobulinemia, including: -- Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG clinical trial 05-180 -- Lead investigator: Steven Treon, M.D., Ph.D., Assistan...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...7:45am; McCormick Place Convention Center, E Arie Crown Theater Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (T...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

...ace Convention Center, S HallA2 Data Presented Sunday, June 3 Oral Presentation: Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia -- J. Soumera; Abstract #8017; June 3, 2007; 1:00-1:15 pm; McCormick Place Convention Center, E354b Oral Presentation: Impact of prior thalidomide (...
Macroglobulinemia in Biological News

Risk of lymphoma increases with hepatitis C virus infection

...ne, found that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain ant...
Macroglobulinemia in Biological Technology

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely ...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

...atory studies of perifosine as a treatment for the following tumor types: renal cell, colon, hepatocellular, multiple myeloma, waldenstrom's macroglobulinemia and sarcoma; -- terminating our license agreement for KRX-0601 (UCN-01); and -- closing the Company's San Francisco, California and Memphis, Ten...

Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma

...more information on multiple myeloma go to http://www.cancer.gov/cancertopics/types/myeloma . About Waldenstrom's Macroglobulinemia Waldenstrom's macroglobulinemia (WM) is a slow-growing type of non-Hodgkin's lymphoma that starts in white blood cells called B lymphocytes. WM is also called lymphoplasmacytic lymph...
Other Tags
(Date:9/17/2014)... Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi ... that influence the risk for developing prostate cancer, according to ... , Prostate cancer is the most common non-skin cancer in ... with the disease in his lifetime. Family history is the ... brother or father with prostate cancer is twice as likely ...
(Date:9/17/2014)... People with facial paralysis are perceived as being ... universal language of facial expression, a new study from ... The findings highlight the important role the face plays ... prejudice against those with facial paralysis because of their ... in the College of Liberal Arts at Oregon State ...
(Date:9/17/2014)... Tools4ever, the market leader ... and Boston Software Systems, leader in healthcare ... Under the agreement, Tools4ever will use ... within its identity and password management solutions. ... automation platforms that streamline complex processes and ...
(Date:9/17/2014)... September 17, 2014. Kessler Foundation is the recipient ... the International Progressive Multiple Sclerosis (MS) Alliance. ... Traumatic Brain Injury Research, is principal investigator of ... of cognitive rehabilitation in individuals with progressive multiple ... grants awarded by the Alliance to investigators in ...
(Date:9/17/2014)... Gerontological Society of America (GSA) invites all journalists ... the country,s largest interdisciplinary conference in the field ... Washington, DC. Media representatives may register free of charge. ... the five-day gathering at the Walter E. Washington Convention ... 2014 is "Making Connections: From Cells to Societies" and ...
Breaking Medicine News(10 mins):Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
(Date:9/16/2014)... rock hit the Yukatan peninsula near the site of the ... of TNT. It left a crater more than 150 km ... are widely accepted to have wiped out the dinosaurs and ... happened to the plants on which the dinosaurs fed? , ... Arizona reveals that the meteorite impact that spelled doom for ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... Three years after the Hesperides vessel returned to Spain ... researchers have an increasingly clear picture of how the ... Specifically, the input of pollutants from the atmosphere is ... the most remote areas of the planet, and it ... findings are presented this week in CSIC Residence for ...
Breaking Biology News(10 mins):Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
Other Contents